FCGR2A and neoplasm: It is generally agreed that direct-targeting mAbs exert their anti-tumor activity by recruiting FcγR-expressing cellular effectors or by blocking oncogenic signaling (Yakes et al., 2002, Gong et al., 2005, Uchida et al., 2004, Beers et al., 2010), whereas immunomodulators either remove inhibitory signaling (checkpoint blockers) or directly stimulate immune effector cells (immunostimulatory mAbs).